Sunobinop

Appearance move to sidebar hide Sunobinop

Clinical data

Other names	IMB-115
Drug class	Nociceptin receptor agonist
Identifiers
IUPAC name 4-nonanyl]-9-azabicyclononan-3-yl]-3-oxoquinoxaline-2-carboxylic acid
CAS Number	1126793-40-5
PubChem CID	155801560
ChemSpider	34950269
UNII	I1X86U5474
ChEMBL	ChEMBL4650344
Chemical and physical data
Formula	C26H33N3O3
Molar mass	435.568 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(O)C1=NC=2C=CC=CC2N(C1=O)C3CC4N(C(CCC4)C3)C5CC6CCCC(C5)C6
InChI InChI=1S/C26H33N3O3/c30-25-24(26(31)32)27-22-9-1-2-10-23(22)29(25)21-14-18-7-4-8-19(15-21)28(18)20-12-16-5-3-6-17(11-16)13-20/h1-2,9-10,16-21H,3-8,11-15H2,(H,31,32)/t16-,17-,18-,19+,21?/m0/s1 Key:COTYYZPYDJKKIS-MCXOOUIESA-N

Sunobinop (developmental code names V117957; IMB-115) is a high affinity small molecule nociceptin receptor partial agonist.

As of Feb 2024, it is under clinical investigation for the treatment of insomnia/alcohol use disorder, interstitial cystitis, and overactive bladder syndrome. It was previously also under investigation for the treatment of fibromyalgia.

Pharmacology

Sunobinop has nanomolar affinity (Ki) and efficacy (EC50) at human recombinant nociceptin/orphanin-FQ peptide (NOP) receptors. It has a high degree of functional selectivity for the NOP receptor. Sunobinop is a low affinity antagonist at human mu and kappa opioid receptors, and is a low affinity weak partial agonist at human delta opioid receptors.

Clinical trials

Sunobinop was generally well tolerated in 3 studies involving 70 healthy subjects at doses that ranged from 0.6 to 30 mg. The most prominent adverse event was dose-dependent sedation/somnolence, which was more common at doses greater than 10 mg. In these studies, most of the absorbed sunobinop was excreted unchanged via rapid renal elimination.

The safety and effectiveness of sunobinop has not been evaluated by the FDA. There is no guarantee that sunobinop will successfully complete development or gain FDA approval.